domvanalimab,etrumadenant,zimberelimab
arcus biosciences
['nsclc', 'sclc', 'arc-7', ' arcus ']
today, the arcus team presented updated data at #asco2023 from our phase 2 arc-7 study evaluating our investigational combination that targets tigit and pd-1 in first-line, metastatic #nsclc. learn more: 
At the forefront of designing novel combination medicines in the pursuit of cures for people living with cancer. View our guidelines: https://t.co/mP1hLQyMnD